In the latest trove of promising Phase III data for Amgen's T-Vec, the cancer-fighting virus increased overall survival by four months compared to standard growth factor therapy, driving optimism that the drug can win approval and make some noise in the melanoma market.
On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving PCSK9 treatments from the likes of Amgen, Sanofi and Regeneron, clearing the way for treatments expected to rake in up to $3 billion a year.
Fresh out of the gate and armed with a $15 million Series A financing, NextCODE Health predicts quick growth through its use of gene sequencing for routine diagnosis of disease initially developed by deCODE genetics. CEO Hannes Smarason said in an interview that the approach is much more viable today due to recent changes in the industry.
With the ink on its $10.4 billion deal for Onyx Pharmaceuticals not yet dry, it might have been exepcted to be the only thing Amgen would key on in its third-quarter earnings today.
The U.S. is one of only two countries that allow direct-to-consumer (DTC) advertising of pharmaceuticals, and opinions on whether doing so is a good idea are all over the place, even among doctors....
One of the programs involved in AstraZeneca's $50 million bid to collaborate with Amgen on the development of a slate of biologics has run into a snafu of some sort. Late last summer investigators reported that a pair of mid-stage trials of AMG 181 for ulcerative colitis and Crohn's disease had been suspended, just after an early-stage trial was reported terminated.
Drug developer Amgen has reached out to KineMed with an eye on neurodegenerative biomarkers, paying to use the California biotech's platform to ferret out the causes of brain cell-killing disorders like Alzheimer's disease.
Amgen and its partner AstraZeneca are headed to a scientific conference in Istanbul this weekend to lay out a slate of upbeat mid-stage data on a closely-watched psoriasis treatment now in Phase III. Top scientists at both companies say that the interleukin-17 targeting brodalumab continued to reflect the initial promise seen in the first round of Phase II data. And they'll be positioning the drug against a heavily competitive field that includes a heavyweight contender from Novartis.
After closing on its $10 billion Onyx buyout earlier in the week, Amgen has now promoted R&D chief Pablo Cagnoni to the president's office. Cagnoni was only hired back in March but gets about a $3.8 million payday in the deal.
If you could bring in former Amgen CEO Kevin Sharer as a consultant, what would he say?